Observational study of FOLFIRINOX therapy for unresectable and recurrence pancreatic cancer
Not Applicable
- Conditions
- unresectable and recurrence pancreatic cancer
- Registration Number
- JPRN-UMIN000014658
- Lead Sponsor
- Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 329
Inclusion Criteria
Not provided
Exclusion Criteria
1) Histologically proven not to be a malignant pancreatic exocrine tumor 2) Not administered all of oxaliplatin, irinotecan, levofolinate calcium and fluorouracil
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method adverse events severe adverse events
- Secondary Outcome Measures
Name Time Method dose intensity, the reasons for dose reduction and delay, progression free survival, overall survival